Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Hope for advanced cancer patients expressed through the lens of Canadian award-winning photojournalists For more media materials please visit:...
Latest approval of OPDIVO® marks the fourth indication for the immuno-oncology treatment offering hope for improved survival to more patients MONTREAL, May 17, 2017 /CNW/ - Health Canada has approved ...
Eligible Ontario residents with difficult-to-treat advanced cancers can now access an innovative new treatment option without having to pay out-of-pocket MONTREAL, March 22, 2017 /CNW/ -...
MONTREAL, March 15, 2017 /CNW/ - Starting today, the province of Manitoba will cover the cost of the immuno-oncology treatment OPDIVO® for eligible patients who have advanced, difficult-to-treat...
MONTREAL, March 2, 2017 /CNW/ - Starting today, the province of British Columbia (BC) will cover the cost of the immuno-oncology treatment OPDIVO® for eligible patients who have advanced,...
Decisions on public reimbursement now in hands of provincial and territorial jurisdictions MONTREAL, Feb. 10, 2017 /CNW/ - Bristol-Myers Squibb Canada Co. today announced that the company has reached ...
Bristol-Myers Squibb receives approval from Health Canada for the OPDIVO® + YERVOY® Regimen for unresectable or metastatic melanoma OPDIVO® + YERVOY® Regimen demonstrates the potential of targeting...
OPDIVO™ is the first immuno-oncology therapy for lung cancer in Canada to use the body's own immune system to fight cancer MONTREAL, June 8, 2016 /CNW/ - Canada's national health technology...
DAKLINZA™ is approved in Canada in combination with other agents for the treatment of chronic hepatitis C Patients with HIV co-infection, advanced cirrhosis and post-liver transplant HCV recurrence...
OPDIVO™ is the first and only anti PD-1 immuno-oncology agent in Canada approved for the treatment of advanced or metastatic renal cell carcinoma to deliver significant overall survival Announcement...
OPDIVO™ is the first and only immuno-oncology therapy in lung cancer in Canada, which uses the body's own immune system to fight cancer, offering improved survival to more patients MONTREAL, March 1, ...
Daclatasvir+sofosbuvir+ribavirin regimen achieves SVR12 rates of 88% and 92% overall for 12 or 16 weeks of therapy respectively in GT-3 patients with advanced fibrosis or cirrhosis MONTREAL, Nov. 16, ...
Priority review approval marks another milestone for Canadians living with this disease MONTREAL, Sept. 25, 2015 /CNW/ - Bristol-Myers Squibb continues to lead with advances in immuno-oncology with...
DAKLINZATM in combination with sofosbuvir is the first 12-week, all-oral therapy that offers SVR12 for the vast majority of non-cirrhotic genotype 3 patients MONTREAL, Aug. 20, 2015 /CNW/ - Health...
Opdivo+Yervoy regimen showed improved outcomes versus Opdivo monotherapy in PD-L1 non- and low-expressers (<5%) MONTREAL, June 3, 2015 /CNW/ - New study results show that superior progression-free...
Opdivo is the first major treatment advance in more than a decade for this disease, showing superior one-year overall survival rate of 42% versus 24% for docetaxel MONTREAL, June 3, 2015 /CNW/ - A...
30% reduction in risk of disease progression or death; 2-year progression-free survival (PFS) rate of 41% in the elotuzumab arm versus 27% in the control arm MONTREAL, June 3, 2015 /CNW/ -...
Opdivo decreased risk of progression or death by 27% compared to standard of care in second positive Phase 3 trial in previously treated patients MONTREAL, June 3, 2015 /CNW/ - A new Bristol-Myers...
Positive results seen in historically difficult-to-treat patients without changing other medications, including those post-transplant with genotypes 1 and 3 MONTREAL, April 29, 2015 /CNW/ - A 12-week ...
Patient population with both infections historically challenging to treat due to drug-drug interactions. MONTREAL, March 3, 2015 /CNW/ - A combination of two once-daily medications for chronic...
Results of study conducted in Canada, Australia and Europe presented at Society for Melanoma Research and published in The New England Journal of Medicine show one-year survival rate of 73% in...
Sustained virologic response after 12 weeks achieved in 90% of treatment-naïve and 86% of treatment-experienced patients in first all-oral, ribavirin-free treatment regimen in difficult-to-treat...
All-oral, 12-week treatment in UNITY-2 trial achieves 98% cure rate in treatment-naïve and 93% in treatment-experienced patients with cirrhosis when used with ribavirin and 93% and 87% respectively...
Immunotherapy treatment with long-term survival in some previously treated patients now approved for use in newly diagnosed patients MONTREAL, Sept. 16, 2014 /CNW/ - Bristol-Myers Squibb Canada is...
Results of the HALLMARK-Dual study include data among genotype 1b cirrhotic and non-cirrhotic, treatment-naive, non-responder, and peginterferon/ribavirin ineligible and intolerant patients Study...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.